← Evidence map

ArticleCancers2025

Long-Acting Recombinant IL-7 (rhIL-7-hyFc) Enhances the Primary and Memory Neoantigen-Specific Immune Response to Breast Cancer Personalized Cancer Vaccines.

Michael Chen et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.

Not cited yet

Long-Acting Recombinant IL-7 (rhIL-7-hyFc) Enhances the Primary and Memory Neoantigen-Specific Immune Response to Breast Cancer Personalized Cancer Vaccines. | OpenQuestion